BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,244,391,850 | -9.9% | 18,281,061 | +8.1% | 0.04% | -5.3% |
| Q2 2023 | $1,380,928,677 | +16.4% | 16,916,926 | +5.8% | 0.04% | +8.6% |
| Q1 2023 | $1,186,641,246 | -9.9% | 15,994,625 | +0.7% | 0.04% | -14.6% |
| Q4 2022 | $1,316,850,492 | +7.2% | 15,888,640 | +267.3% | 0.04% | -2.4% |
| Q3 2022 | $1,228,662,000 | -17.3% | 4,326,270 | +0.9% | 0.04% | -12.5% |
| Q2 2022 | $1,486,255,000 | -22.1% | 4,287,606 | -2.6% | 0.05% | -5.9% |
| Q1 2022 | $1,907,014,000 | -14.8% | 4,403,779 | +1.7% | 0.05% | -10.5% |
| Q4 2021 | $2,239,202,000 | +6.2% | 4,328,299 | -0.5% | 0.06% | -3.4% |
| Q3 2021 | $2,108,962,000 | -10.4% | 4,352,235 | -16.8% | 0.06% | -10.6% |
| Q2 2021 | $2,354,260,000 | +34.7% | 5,228,672 | +14.3% | 0.07% | +29.4% |
| Q1 2021 | $1,747,172,000 | +26.5% | 4,574,590 | +5.2% | 0.05% | +15.9% |
| Q4 2020 | $1,380,715,000 | +19.3% | 4,348,028 | -7.0% | 0.04% | +2.3% |
| Q3 2020 | $1,157,710,000 | -7.1% | 4,673,274 | -1.0% | 0.04% | -14.0% |
| Q2 2020 | $1,246,330,000 | +77.6% | 4,719,699 | +27.5% | 0.05% | +47.1% |
| Q1 2020 | $701,937,000 | -16.1% | 3,701,808 | -2.9% | 0.03% | +6.2% |
| Q4 2019 | $836,588,000 | +13.2% | 3,811,161 | +0.9% | 0.03% | +3.2% |
| Q3 2019 | $738,979,000 | -7.0% | 3,776,662 | -0.9% | 0.03% | -8.8% |
| Q2 2019 | $794,629,000 | +4.6% | 3,811,354 | -0.4% | 0.03% | 0.0% |
| Q1 2019 | $759,611,000 | +36.1% | 3,825,798 | -0.8% | 0.03% | +21.4% |
| Q4 2018 | $558,034,000 | -27.5% | 3,855,948 | +2.3% | 0.03% | -15.2% |
| Q3 2018 | $769,569,000 | +37.7% | 3,770,358 | -0.2% | 0.03% | +26.9% |
| Q2 2018 | $558,726,000 | +0.4% | 3,776,455 | +2.5% | 0.03% | -3.7% |
| Q1 2018 | $556,573,000 | +20.1% | 3,684,936 | +3.0% | 0.03% | +22.7% |
| Q4 2017 | $463,606,000 | +7.2% | 3,578,581 | +0.0% | 0.02% | 0.0% |
| Q3 2017 | $432,575,000 | +3.4% | 3,578,249 | +0.5% | 0.02% | 0.0% |
| Q2 2017 | $418,485,000 | +17.6% | 3,561,574 | +1.7% | 0.02% | +10.0% |
| Q1 2017 | $355,820,000 | +14381.9% | 3,500,436 | +14548.6% | 0.02% | +566.7% |
| Q4 2016 | $2,457,000 | -6.9% | 23,896 | -0.9% | 0.00% | -25.0% |
| Q3 2016 | $2,640,000 | +17.6% | 24,113 | +21.2% | 0.00% | +33.3% |
| Q2 2016 | $2,244,000 | +48.4% | 19,898 | +24.3% | 0.00% | +50.0% |
| Q1 2016 | $1,512,000 | +26.7% | 16,008 | +20.6% | 0.00% | 0.0% |
| Q4 2015 | $1,193,000 | +1.6% | 13,269 | +4.5% | 0.00% | 0.0% |
| Q3 2015 | $1,174,000 | -4.3% | 12,698 | +1.9% | 0.00% | 0.0% |
| Q2 2015 | $1,227,000 | +0.4% | 12,460 | +2.3% | 0.00% | 0.0% |
| Q1 2015 | $1,222,000 | +14.8% | 12,183 | +5.9% | 0.00% | 0.0% |
| Q4 2014 | $1,064,000 | – | 11,505 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |